NexgenRx Inc.

As of June 30, 2026, NexgenRx Inc. carries a market capitalization of 32.00M, placing it among publicly traded companies globally. Its enterprise value stands at 30.36M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, NexgenRx Inc. has 71.12M shares outstanding.

As of June 30, 2026, NexgenRx Inc. trades at a trailing price-to-earnings ratio of 12.50. The price-to-sales ratio is 1.71, and the price-to-book ratio stands at 4.14.

As of June 30, 2026, NexgenRx Inc. trades at an EV/EBITDA multiple of 6.76 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 8.80 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. NexgenRx Inc. trades at an EV/FCF ratio of 9.97, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 30.36M versus a market cap of 32.00M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, NexgenRx Inc. maintains a current ratio of 1.15, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.97, indicating elevated leverage, while an interest coverage ratio of 207.25 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, NexgenRx Inc. posted a return on equity (ROE) of 37.11, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 30.44 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.44, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 29.11, useful for judging operating efficiency across full business cycles.

Over the twelve months ended June 30, 2026, NexgenRx Inc. recorded 645,841.00 in income tax expense. That works out to an effective tax rate of 19.71, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 3.28M, leaving 2.63M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 7, 2026, NexgenRx Inc.'s stock has gained approximately 72.60% over the past 52 weeks.

Over the twelve months ended June 30, 2026, NexgenRx Inc. generated 19.19M in revenue and converted that into 2.63M in net income, yielding earnings per share of 0.03. EBITDA reached 4.49M, while operating income came in at 3.62M.

As of June 30, 2026, NexgenRx Inc. holds 3.57M in cash and equivalents against 279,259.00 in total debt, resulting in a net debt position of -3.57M. Total book value stands at 7.74M, with working capital of 5.54M providing operational flexibility.

NexgenRx Inc. produced 3.25M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -224,853.00 in capital expenditures, free cash flow totaled 3.03M - equivalent to 0.04 per share.

Over the twelve months ended June 30, 2026, NexgenRx Inc. posted a gross margin of 85.54, reflecting its pricing power and cost economics. The operating margin of 18.85 and net profit margin of 13.70 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, NexgenRx Inc. paid dividends of 0.02 per share. The dividend payout ratio of 50.59 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 8.54, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.44, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to NexgenRx Inc. shareholders.

As of June 30, 2026, NexgenRx Inc. has an Altman Z-Score of 1.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.